[Transurethral needle ablation (TUNA) in benign prostatic hypertrophy: 2-year follow-up].
In this study we have evaluated the effectiveness, safety and tolerability of TUNA in the long term follow-up. We have evaluated 24 patients, aged between 66 and 81 years (mean age 73, 4 yrs) with a mean prostatic volume of 57 ml (range 33-140 mls). Before treatment, urodynamic investigation (max flow rate), residual volume, PSA, IPSS and quality of life tests have been performed in all patients. After treatment, all the patient have been evaluated at 6, 12 and 24 months by the same parameters. Based on our experience, we can say that the results obtained after 24 months are similar to those observed 12 months after treatment, except a slight increase in IPSS and quality of life tests in patients older than 70 years, with a baseline maximal detrusorial pressure > 60 cm H2O, with a baseline residual urine > 100 cc and with a baseline quality of life = 5.
Minardi
D
D
Clinica Urologica, Università degli Studi, Ancona.
Garofalo
F
F
Yehia
M
M
Baldassari
M
M
Muzzonigro
G
G
Polito
M
M
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D004564:Electrocoagulation / Q000295:instrumentation / Q000379:methods*; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000601:surgery*; D011788:Quality of Life; D014563:Urodynamics
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen